Abstract
Introduction Pediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 90%, while adult ALL has a 3-year survival rate of only 40–50%. Adolescents and young adults (AYAs) face unique challenges due to age-related factors and high-risk disease features. Although pediatric-inspired regimens improve survival, intensive chemotherapy increases susceptibility to severe infections.
Methods A retrospective analysis was conducted on AYA-ALL patients treated at Chiang Mai University Hospital from 1 January 2007 to 31 December 2023. Patients were classified into pediatric-inspired (TPOG) or adult regimens (Hyper-CVAD or GMALL). Infections were categorized as clinically documented infections (CDI) or microbiologically documented infections (MDI). Multivariate logistic regression was used to identify infection risk factors.
Results Among 94 patients (62.8% male; median age 22.9 years), 56.4% received TPOG and 43.6% received adult regimens. Infectious complications occurred in 79.8% of patients, with higher rates in the adult regimen group (90.2% vs. 71.7%, p = 0.03). CDI was more frequent in the adult group (73.4% vs. 52.8%, p = 0.04), while fungal infections were more common in the TPOG group (26.4% vs. 9.8%, p = 0.04). Adult regimens significantly increased infection risk (OR 3.55; 95% CI 1.02–12.36, p = 0.04). Infection rates peaked during induction (47.8%) and consolidation (51.8%). During induction, MDI was lower in the adult group (21% vs. 79%, p = 0.01), while CDI was higher during consolidation (69% vs. 30%, p < 0.01). Gram-negative bacteria were the most common pathogens (85%), particularly E. coli (27%) and Salmonella spp. (21%). Fungal infections affected 19.1% of patients, with invasive pulmonary aspergillosis being the most common (11.7%).
Conclusion AYA-ALL patients are highly susceptible to infections, especially those receiving adult regimens. Fungal infections were notably more common in patients on the TPOG regimen. Strengthening infection prevention and providing early treatment are vital for improving patient outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional ethical review board of the Faculty of Medicine, Chiang Mai University, Thailand, approved the study (study code: MED-2566-0630).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.